Fig. 3

Distribution of patients by Type 2 inflammation biomarkers* [Elaborated from [29]]. In the QUEST trial, 71.5% of the patients had EOS ≥ 150 cells/μL; 50.2% had FeNO ≥ 25 ppb and 57.7% were allergic (IgE ≥ 30 IU/mL). 24.8% of the patient population presented at baseline EOS ≥ 150 cells/μL and FeNO ≥ 25 ppb and IgE ≥ 30 IU/mL. 64.0% of the patient population presented an increase of at least two of the three identified relevant biomarkers at baseline (41.6% had EOS ≥ 150 cells/μL and FeNO ≥ 25 ppb). 26.6% of the patient population presented an increase of only one of the three identified relevant biomarkers at baseline